UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
PROXY STATEMENT PURSUANT TO SECTION 14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934
Filed by the Registrant þ
Filed by a Party other than the Registrant o
Check the appropriate box:
 	 	 	
o	 	Preliminary Proxy Statement	
o	 	Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e) (2) )	
þ	 	Definitive Proxy Statement	
o	 	Definitive Additional Materials	
o	 	Soliciting Material Under Rule 14a-12	
Halozyme Therapeutics, Inc.
 
(Name of Registrant as Specified in Its Charter)
 
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box) :
 	 	 	
þ	 	No fee required.	
o	 	Fee computed on table below per Exchange Act Rules 14a-6(i) (1) and 0-11.	
 	 	 	 	 	 	 	
 	 	 	(1	)	 	Title of each class of securities to which transaction applies:	

 	 	 	 	 	 	 	
 	 	 	(2	)	 	Aggregate number of securities to which transaction applies:	

 	 	 	 	 	 	 	
 	 	 	(3	)	 	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):	

 	 	 	 	 	 	 	
 	 	 	(4	)	 	Proposed maximum aggregate value of transaction:	

 	 	 	 	 	 	 	
 	 	 	(5	)	 	Total fee paid:	

 	 	 	
o	 	Fee paid previously with preliminary materials:	
 	 	 	
o	 	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a) (2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.	
 	 	 	 	 	 	 	
 	 	 	(1	)	 	Amount previously paid:	

 	 	 	 	 	 	 	
 	 	 	(2	)	 	Form, Schedule or Registration Statement No.:	

 	 	 	 	 	 	 	
 	 	 	(3	)	 	Filing Party:	

 	 	 	 	 	 	 	
 	 	 	(4	)	 	Date Filed:	

 

TABLE OF CONTENTS

									
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS	
PROXY STATEMENT FOR ANNUAL MEETING OF STOCKHOLDERS	
SOLICITATION AND VOTING	
PROPOSAL NO. 1 ELECTION OF DIRECTORS	
CORPORATE GOVERNANCE	
PROPOSAL NO. 2 RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM	
PRINCIPAL ACCOUNTING FEES AND SERVICES	
REPORT OF THE AUDIT COMMITTEE	
EXECUTIVE COMPENSATION	
	Compensation Discussion and Analysis	
	Compensation Committee Report	
2008 SUMMARY COMPENSATION TABLE	
2008 GRANTS OF PLAN-BASED AWARDS	
OUTSTANDING EQUITY AWARDS AT DECEMBER 31, 2008	
OPTION EXERCISES AND STOCK VESTED	
2008 DIRECTOR COMPENSATION	
EQUITY COMPENSATION PLAN INFORMATION	
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS	
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS	
COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT	
STOCKHOLDER PROPOSALS TO BE PRESENTED AT NEXT ANNUAL MEETING	
TRANSACTION OF OTHER BUSINESS	

 
April 2, 2009
 
Dear Fellow Stockholder:
 
This year’s annual meeting of stockholders will be held on Thursday, May 7, 2009, at 8:00 a.m. local time, at the Halozyme Conference Center, 11404 Sorrento Valley Road, San Diego, California 92121. You are cordially invited to attend.
 
The Notice of Annual Meeting of Stockholders and a Proxy Statement, which describes the formal business to be conducted at the meeting, follow this letter.
 
It is important that you use this opportunity to take part in the affairs of Halozyme Therapeutics, Inc. by voting on the business to come before this meeting. After reading the Proxy Statement, please promptly mark, sign, date and return the enclosed proxy card in the prepaid envelope to assure that your shares will be represented. Regardless of the number of shares you own, your careful consideration of, and vote on, the matters before our stockholders is important.
 
A copy of Halozyme’s Annual Report to Stockholders is also enclosed for your information. At the annual meeting we will review Halozyme’s activities over the past year and our plans for the future. The Board of Directors and management look forward to seeing you at the annual meeting.
 
Sincerely yours,
 
Jonathan E. Lim, M.D.
 
President and Chief Executive Officer

 

 
11388 Sorrento Valley Road
San Diego, California 92121
 
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
To Be Held on May 7, 2009
 
TO OUR STOCKHOLDERS:
 
Notice is hereby given that the annual meeting of the stockholders of Halozyme Therapeutics, Inc., a Delaware corporation, will be held on May 7, 2009, at 8:00 a.m. local time, at the Halozyme Conference Center, 11404 Sorrento Valley Road, San Diego, California 92121, for the following purposes:
 
1. To elect two Class II directors to hold office for a three-year term and until their respective successors are elected and qualified.
 
2. To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2009.
 
3. To transact such other business as may properly come before the meeting.
 
Only stockholders of record at the close of business on April 1, 2009 are entitled to notice of, and to vote at, this meeting and any adjournment or postponement thereof.
 
David A. Ramsay
 
Chief Financial Officer and Secretary
 
San Diego, California
April 2, 2009

IMPORTANT: Please fill in, date, sign and promptly mail the enclosed proxy card in the accompanying postage-paid envelope to assure that your shares are represented at the meeting. If you attend the meeting, you may choose to vote in person even if you have previously sent in your proxy card.

 

 
 
PROXY STATEMENT FOR ANNUAL MEETING OF STOCKHOLDERS
 
The accompanying proxy is solicited by the Board of Directors of Halozyme Therapeutics, Inc., a Delaware corporation, for use at its annual meeting of stockholders to be held on May 7, 2009, or any adjournment or postponement thereof, for the purposes set forth in the accompanying Notice of Annual Meeting of Stockholders. This Proxy Statement and the enclosed proxy are being mailed to stockholders on or about April 2, 2009.
 
SOLICITATION AND VOTING
 
Voting Securities.   Only stockholders of record as of the close of business on April 1, 2009, will be entitled to vote at the meeting and any adjournment thereof. As of that time, we had 82,946,637 shares of common stock outstanding, all of which are entitled to vote with respect to all matters to be acted upon at the annual meeting. Each stockholder of record as of that date is entitled to one vote for each share of common stock held by him or her. Our Bylaws provide that a majority of all of the shares of the stock entitled to vote, whether present in person or represented by proxy, shall constitute a quorum for the transaction of business at the meeting. Votes for and against, abstentions and “broker non-votes” will each be counted as present for purposes of determining the presence of a quorum.
 
Broker Non-Votes.   A broker non-vote occurs when a broker submits a proxy card with respect to shares held in a fiduciary capacity (typically referred to as being held in “street name”) but declines to vote on a particular matter because the broker has not received voting instructions from the beneficial owner. Under the rules that govern brokers who are voting with respect to shares held in street name, brokers have the discretion to vote such shares on routine matters, but not on non-routine matters. Routine matters include the election of directors, increases in authorized common stock for general corporate purposes and ratification of auditors. Non-routine matters include adoptions of, and amendments to, stock plans.
 
Solicitation of Proxies.   We will bear the entire cost of soliciting proxies for the upcoming meeting. In addition to soliciting stockholders by mail through our employees, we will request banks, brokers and other custodians, nominees and fiduciaries to solicit customers for whom they hold our stock and will reimburse them for their reasonable, out-of-pocket costs. We may use the services of our officers, directors and others to solicit proxies, personally or by telephone, without additional compensation. In addition, we may retain a proxy solicitation firm or other third party to assist us in collecting or soliciting proxies from our stockholders, although we do not currently plan on retaining such a proxy solicitor.
 
Voting of Proxies.   All valid proxies received before the meeting will be exercised. All shares represented by a proxy will be voted, and where a proxy specifies a stockholder’s choice with respect to any matter to be acted upon, the shares will be voted in accordance with that specification. If no choice is indicated on the proxy, the shares will be voted in favor of each proposal. A stockholder giving a proxy has the power to revoke it at any time before it is exercised by delivering to the Secretary of Halozyme a written instrument revoking the proxy or a duly executed proxy with a later date, or by attending the meeting and voting in person.

 
 
PROPOSAL NO. 1
 
ELECTION OF DIRECTORS
 
We have a classified Board of Directors that consists of three Class I directors, three Class II directors and three Class III directors. Our directors are elected for a term of three years, with one class of directors up for election every year. At the 2009 annual meeting of stockholders we will be electing two Class II directors, while three Class III directors will be elected at the 2010 annual meeting of stockholders and three Class I directors will be elected at the 2011 annual meeting of stockholders. Once elected, directors serve until their respective successors are duly elected and qualified.
 
The Class II nominees recommended by the Board of Directors for election at the 2009 annual meeting are Randal J. Kirk and John S. Patton. Steven T. Thornton, a current Class II director, will not be standing for reelection. Mr. Kirk and Dr. Patton are all current members of our Board of Directors and, if elected, they will serve as directors until our annual meeting of stockholders in 2012 and until their successors are elected and qualified. Because the Nominating and Governance Committee has only recently begun to review potential candidates to replace Mr. Thornton, there will be one vacant Class II director seat following the 2009 annual meeting. The seat will be filled once an appropriate candidate has been identified pursuant to the existing policies of the Nominating and Governance Committee and the Board of Directors. If any other nominee declines to serve or becomes unavailable for any reason, or if a vacancy occurs before the election (although we know of no other reason to anticipate that this will occur), the proxies may be voted for such substitute nominees as we may designate.
 
If a quorum is present and voting, the two nominees for Class II directors receiving the highest number of votes will be elected as the Class II directors. Abstentions and broker non-votes have no effect on the vote.
 
The Board of Directors recommends a vote “FOR” each of the nominees named above.
 
The following table sets forth biographical information for the two Class II nominees to be elected at this meeting as well as all other directors who will continue serving on the Board of Directors following this meeting:

 	 	 	 	 	 	Director	
Name	 	Principal Occupation	 	Age	 	Since	
 		
Class II directors nominated for election at the 2009 annual meeting of stockholders:	 	 	 	 	 	 	 	 	
Randal J. Kirk	 	Chief Executive Officer, Third Security, LLC	 	 	55	 	 	 	2007	 	
John S. Patton, Ph.D. 	 	President, Dance Pharmaceuticals	 	 	62	 	 	 	2000	 	
Class III directors whose terms expire at the 2010 annual meeting of stockholders:	 	 	 	 	 	 	 	 	
Robert L. Engler, M.D. 	 	Professor Emeritus, University of California, San Diego	 	 	64	 	 	 	2004	 	
Gregory I. Frost, Ph.D	 	Vice President, Chief Scientific Officer, Halozyme Therapeutics, Inc.	 	 	37	 	 	 	1999	 	
Connie L. Matsui	 	Independent Consultant	 	 	55	 	 	 	2006	 	
Class I directors whose terms expire at the 2011 annual meeting of stockholders:	 	 	 	 	 	 	 	 	
Kathryn E. Falberg	 	Chief Financial Officer and Chief Operating Officer, ARCA biopharma, Inc.	 	 	48	 	 	 	2007	 	
Kenneth J. Kelley	 	Managing Director, K2 Bioventures	 	 	50	 	 	 	2004	 	
Jonathan E. Lim, M.D. 	 	President and Chief Executive Officer, Halozyme Therapeutics, Inc.	 	 	37	 	 	 	2003	 	

Directors Nominated for Election at the 2009 Annual Meeting
 
Randal J. Kirk.   Mr. Kirk has served as the Senior Managing Director and Chief Executive Officer of Third Security, LLC, an investment management firm founded by Mr. Kirk, since March 1999. Additionally, Mr. Kirk founded and became Chairman of the Board of Directors of New River Pharmaceuticals Inc. (previously traded on Nasdaq prior to its acquisition by Shire plc in 2007) in 1996, and was President and Chief Executive Officer between October 2001 and April 2007. Mr. Kirk began his professional career in the private practice of law. Mr. Kirk served as a member of the Board of Directors of Scios, Inc. (previously traded on Nasdaq prior to its acquisition by

2

 

Johnson & Johnson) between February 2000 and May 2002. Mr. Kirk currently serves in a number of additional capacities including as Chairman of the Board of Directors of Clinical Data, Inc. (Nasdaq: CLDA) since December 2004 and as a member of the Board of Directors since September 2002; as Chairman of the Board of Directors of Intrexon Corporation since February 2008; and as Chairman of the Board of Directors of Cyntellect, Inc. since September 2008. Mr. Kirk has served on the Board of Visitors of Radford University since July 2003, was elected Rector of the Board from September 2006 to September 2008, and also has served on the Board of Directors of the Radford University Foundation, Inc. since September 1998. He was appointed to the Virginia Advisory Council on Revenue Estimates in July 2006, and was appointed as a member of the Board of Directors of the Virginia University Research Partnership in July 2007. Mr. Kirk received a B.A. in Business from Radford University and a J.D. from the University of Virginia. Mr. Kirk serves on the Compensation Committee and the Nominating and Governance Committee.
 
John S. Patton, Ph.D.   Dr. Patton is currently the founder and President of Dance Pharmaceuticals. Prior to Dance Pharmaceuticals, Dr. Patton co-founded Nektar Therapeutics (Nasdaq-NKTR) (formerly Inhale Therapeutic Systems) and he served as Chief Scientific Officer from November 2001, and as a director from 1990, through 2008. He is an expert in the delivery of peptides and proteins. Before co-founding Nektar Therapeutics, Dr. Patton led the drug delivery group at Genentech, Inc., where he demonstrated the feasibility of systemic delivery of large molecules through the lungs. Prior to joining Genentech, Inc., he was a tenured professor at the University of Georgia. He has published a wide range of articles and has presented his work in national and international arenas. Dr. Patton received his Ph.D. in Biology from the University of California, San Diego, and held post-doctoral positions in biomedicine at Harvard Medical School and the University of Lund in Sweden. Dr. Patton chairs our Scientific and Clinical Advisory Board.
 
Directors Elected to Continue in Office Until the 2010 Annual Meeting
 
Robert L. Engler, M.D.   Dr. Engler spent his career as a Cardiologist at the Veterans Affairs Medical Center and the University of California, San Diego, where he retired as Professor Emeritus in 2001. While at the Veterans Affairs Medical Center, Dr. Engler served as Associate Chief of Staff and Chief of Research and was an attending physician, in addition to running an active cardiovascular research laboratory. His research and clinical work led to the founding of two successful biotechnology companies: Gensia, Inc., and Collateral Therapeutics, Inc. He also founded and served as President of the Veterans Medical Research Foundation. Dr. Engler graduated from Georgetown Medical School. Dr. Engler is the Chair of our Nominating and Governance Committee.
 
Gregory I. Frost, Ph.D.   Dr. Frost co-founded Halozyme in 1999 and currently serves as Vice President, Chief Scientific Officer. Dr. Frost has spent more than twelve years researching the hyaluronidase family of enzymes. Previously he was a Senior Research Scientist at the Sidney Kimmel Cancer Center (SKCC), where he focused much of his work developing the hyaluronidase technology. Prior to SKCC, his research in the Department of Pathology at the University of California, San Francisco, led directly to the purification, cloning, and characterization of the human hyaluronidase gene family, and the discovery of several metabolic disorders. He has authored multiple scientific peer-reviewed and invited articles in the hyaluronidase field and is an inventor on several key patents. Dr. Frost’s prior experience includes serving as a scientific consultant to a number of biopharmaceutical companies, including Q-Med (SE), Biophausia AB (SE), and Active Biotech (SE). Dr. Frost is registered to practice before the US Patent Trademark Office, and earned a B.A. in Biochemistry and Molecular Biology from the University of California, Santa Cruz and a Ph.D. in the Department of Pathology at the University of California, San Francisco, where he was an ARCS-Scholar.
 
Connie L. Matsui.   Ms. Matsui has over 16 years of general management experience in the biotechnology industry. Prior to her retirement in January 2009, she was the Executive Vice President, Knowledge and Innovation Networks for Biogen Idec, Inc. She served in several positions since joining IDEC Pharmaceuticals in November 1992, including Senior Vice President, overseeing investor relations, corporate communications, human resources, project management and strategic planning. Prior to entering the biotechnology industry, Ms. Matsui worked for Wells Fargo Bank in general management, marketing and human resources. Ms. Matsui has been active on a number of not-for-profit boards and served as National President of the Girl Scouts of the USA from 1999 to 2002. Ms. Matsui earned B.A. and M.B.A. degrees from Stanford University.

3

 

Directors Elected to Continue in Office Until the 2011 Annual Meeting
 
Kathryn E. Falberg.   Ms. Falberg joined ARCA biopharma, Inc. (Nasdaq: ABIO) in February 2009 as its Chief Financial Officer and Chief Operating Officer. From 2003 to 2008 Ms. Falberg was President of Canyon Capital & Consulting, a private investment and consulting firm. From October 2001 to June 2002 Ms. Falberg was a consultant to Inamed, a medical device company, and briefly served as its interim Chief Financial Officer. Ms. Falberg joined Amgen Inc., a global biotechnology company, in 1995 as Treasurer, and advanced through a series of positions of increasing responsibility, culminating in her appointment as Senior Vice President, Finance and Strategy, and Chief Financial Officer in 1998. Ms. Falberg left Amgen Inc. in July 2001. Ms. Falberg has served on the board of directors for companies in multiple industries and she currently serves on the board of QLT, Inc. (Nasdaq:QLTI) and ESS Technology, a privately held semiconductor company. Ms. Falberg received an M.B.A. and B.A. in Economics from the University of California, Los Angeles. Ms. Falberg is the Chair of the Audit Committee and she also serves on the Nominating and Governance Committee.
 
Kenneth J. Kelley.   Mr. Kelley brings over 25 years of entrepreneurial, venture capital, operational and technical biotechnology experience to Halozyme. Mr. Kelley has been the managing director of K2 Bioventures, a biomedical startup consulting company, since July 2004. Mr. Kelley currently serves as the Chief Executive Officer and Chair of the Board of Directors of privately held PaxVax, Inc. From April 2002 through June 2004, Mr. Kelley was a General Partner at Latterell Venture Partners, where he made investments in early stage biotechnology and medical device startups. Mr. Kelley founded IntraBiotics Pharmaceuticals in January 1994 and over eight years served as CEO, Director and Chair of the Board of Directors. Earlier, Mr. Kelley was an Associate at Institutional Venture Partners (IVP), where he participated in the financing of twenty biotech and medical companies, fifteen of which became public companies. Prior to IVP, he was a consultant for McKinsey & Company and a scientist at Integrated Genetics (acquired by Genzyme). Mr. Kelley earned an M.B.A. from Stanford University and a B.A. in Biochemical Sciences from Harvard University. Mr. Kelley is the Chair of the Board of Directors and he also serves on the Audit Committee and the Compensation Committee.
 
Jonathan E. Lim, M.D.   Dr. Lim joined Halozyme in 2003 and has served as Halozyme’s President and Chief Executive Officer since that time. From 2001 to 2003, Dr. Lim was a management consultant at McKinsey & Company, where he specialized in the health care industry, serving a wide range of start-ups to Fortune 500 companies in the biopharmaceutical, medical products, and payor/provider segments. From 1999 to 2001, Dr. Lim was a recipient of a National Institutes of Health Postdoctoral Fellowship, during which time he conducted clinical outcomes research at Harvard Medical School. He has published articles in peer-reviewed medical journals such as the Annals of Surgery and the Journal of Refractive Surgery. Dr. Lim’s prior experience also includes two years of clinical training in general surgery at the New York Hospital-Cornell Medical Center and Memorial Sloan-Kettering Cancer Center; Founder and President of a health care technology start-up company; Founding Editor-in-Chief of the McGill Journal of Medicine; and basic science and clinical research at the Salk Institute for Biological Studies and Massachusetts Eye and Ear Infirmary. Dr. Lim is currently a California-licensed physician and is a volunteer surgeon in his spare time. He was a member of the strategic planning committee of the American Medical Association from 2002 to 2005. He earned a B.S., with honors, and an M.S. in Molecular Biology from Stanford University, an M.D. from McGill University, and an M.P.H. in Health Care Management from Harvard University.
 
CORPORATE GOVERNANCE
 
Director Independence
 
The Board of Directors (the “Board”) has determined that, other than Dr. Lim, Dr. Frost and Ms. Matsui, each of the members of the Board of Directors is an independent director for purposes of the listing requirements of the Nasdaq Marketplace Rules. Drs. Lim and Frost are employees of Halozyme and Ms. Matsui has an indirect financial interest in an entity that leases office and research facilities to Halozyme.
 
Executive Sessions
 
Our independent directors meet in executive session without management present each time the Board holds its regularly scheduled meetings. Mr. Kelley, as Chair of the Board of Directors, acts as the presiding director for such executive sessions of independent directors.

4

 

Board Meetings and Committees
 
The Board of Directors held six meetings during the fiscal year ended December 31, 2008. The Board of Directors has three committees: (i) Audit Committee; (ii) Compensation Committee; and (iii) Nominating and Governance Committee. During the last fiscal year, each director attended at least 75% of the total number of meetings of the Board and all of the committees of the Board on which such director served during that period.
 
Audit Committee.
 
The members of the Audit Committee are Kathryn E. Falberg (Chair), Kenneth J. Kelley and Steven T. Thornton. All members of the Audit Committee satisfy the independence requirements established by the Nasdaq Marketplace Rules. Ms. Falberg is an “audit committee financial expert,” as defined in the rules of the Securities and Exchange Commission. The Audit Committee operates under a written charter that is available on our website at: www.halozyme.com . The Audit Committee conducts an annual review of this charter in addition to an annual review of the committee’s overall performance. The primary purpose of the Audit Committee is to oversee our accounting and financial reporting processes and the function of the Audit Committee includes retaining our independent auditors, reviewing their independence, reviewing and approving the planned scope of our annual audit, reviewing and approving any fee arrangements with our auditors, overseeing their audit work, reviewing and pre-approving any non-audit services that may be performed by them, reviewing the adequacy of accounting and financial controls, reviewing our critical accounting policies and reviewing and approving any related party transactions. The Audit Committee held four meetings during the fiscal year ended December 31, 2008.
 
Additional information regarding the Audit Committee is set forth in the Report of the Audit Committee immediately following Proposal No. 2.
 
Compensation Committee.
 
The members of the Compensation Committee are Steven T. Thornton (Chair), Randal J. Kirk and Kenneth J. Kelley. All members of the Compensation Committee satisfy the independence requirements established by the Nasdaq Marketplace Rules. The Compensation Committee operates under a written charter that is available on our website at: www.halozyme.com . The Compensation Committee conducts an annual review of this charter in addition to an annual review of the committee’s overall performance. The primary purpose of the Compensation Committee is to discharge the Board’s responsibilities relating to compensation and benefits of our executive officers. More specifically, the Compensation Committee: reviews and determines the salary and bonus earned by the Chief Executive Officer; reviews and determines salary and bonus levels for other executive officers; approves stock option grants to executive officers and other employees; approves employment and severance agreements; and reviews the compensation of outside directors for service on the Board of Directors and its committees and recommends changes in compensation for outside directors. The Compensation Committee held six meetings during the fiscal year ended December 31, 2008.
 
Nominating and Governance Committee.
 
The members of the Nominating and Governance Committee are Robert L. Engler (Chair), Kathryn E. Falberg and Randal J. Kirk. All members of the Nominating and Governance Committee satisfy the independence requirements established by the Nasdaq Marketplace Rules. The Nominating and Governance Committee operates under a written charter that is available on our website at: www.halozyme.com . The Nominating and Governance Committee conducts an annual review of this charter in addition to an annual review of the committee’s overall performance. The primary responsibilities of the Nominating and Governance Committee are to (i) identify individuals qualified to become Board members; (ii) select, or recommend to the Board, director nominees for each election of directors; (iii) develop and recommend to the Board criteria for selecting qualified director candidates; (iv) consider committee member qualifications, appointment and removal; (v) recommend applicable corporate governance principles, codes of conduct and compliance mechanisms, and (vi) provide oversight in the evaluation of the Board and each committee. The Nominating and Governance Committee held four meetings during the fiscal year ended December 31, 2008.

5

 

The Nominating and Governance Committee’s goal is to assemble a Board of Directors that brings a variety of perspectives and skills derived from high quality business and professional experience. There are no stated minimum criteria for director nominees, but the Nominating and Governance Committee believes that at least one member of the Board meet the criteria for an “audit committee financial expert” as defined by SEC rules, and that a majority of the members of the Board meet the definition of “independent director” under the Nasdaq Marketplace Rules. The Nominating and Governance Committee also believes it appropriate for certain key members of management to participate as members of the Board.
 
When considering whether to recommend any candidate for inclusion in the Board’s slate of recommended director nominees, including candidates recommended by our stockholders, the Nominating and Governance Committee will review the candidate’s integrity, business acumen, age, experience, commitment, diligence, conflicts of interest, existing time commitments and the ability to act in the interests of all stockholders. Once a potential qualified candidate is identified, multiple members of the Nominating and Governance Committee will interview that candidate. The committee may also ask the candidate to meet with non-committee members of the Board and/or members of management and, if the committee believes a candidate would be a valuable addition to the Board, it will recommend that candidate to the full Board.
 
Pursuant to the terms of its charter, the Nominating and Governance Committee will consider qualified director candidates suggested by our stockholders. Stockholders may recommend individuals for the Nominating and Governance Committee to consider as potential director candidates by submitting the candidate’s name, contact information and biographical information in writing to the “Halozyme Nominating and Governance Committee” c/o Corporate Secretary, 11388 Sorrento Valley Road, San Diego, California 92121. The biographical information and background materials will be forwarded to the Nominating and Governance Committee for its review and consideration. The committee’s review process for candidates identified by our stockholders is essentially identical to the review process for candidates identified by the committee. The Nominating and Governance Committee will review periodically whether a more formal policy regarding stockholder nominations should be adopted. In addition to the process discussed above regarding the consideration of the Nominating and Governance Committee of candidates suggested by our stockholders, our Bylaws contain provisions that address the process by which a stockholder may nominate an individual to stand for election to our Board at our annual meeting of stockholders.
 
Communications with Directors
 
Any stockholder who desires to contact any members of our Board of Directors may do so by writing to: Board of Directors, c/o Corporate Secretary, 11388 Sorrento Valley Road, San Diego, California 92121. Communications received in writing are distributed to the Chair of the Board or the other members of the Board as appropriate depending on the facts and circumstances outlined in the communication received. Alternatively, any stockholder who desires to contact an independent member of our Board of Directors directly, may contact the Chair of our Board of Directors, Kenneth J. Kelley, electronically by sending an email to the following address: kkelley@halozyme.com.
 
Director Attendance at Annual Meetings
 
Although we do not have a formal policy regarding attendance by members of the Board at our annual meeting of stockholders, we encourage directors to attend. Directors Frost, Kelley, Lim and Matsui attended our annual meeting of stockholders in 2008.
 
Code of Conduct and Ethics
 
The Board has adopted a Code of Conduct and Ethics that applies to all of our employees, officers and directors. A copy of our Code of Conduct and Ethics is currently available on our website at: www.halozyme.com.
 
www.halozyme.com
 
Please note that the information on our website is not incorporated by reference in this Proxy Statement.

6

 
 
PROPOSAL NO. 2
 
RATIFICATION OF SELECTION OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
The Audit Committee of the Board of Directors of Halozyme has selected Ernst & Young LLP as the independent registered public accounting firm to audit the consolidated financial statements of Halozyme for the fiscal year ending December 31, 2009. Ernst & Young LLP has acted in such capacity since its appointment on June 28, 2006. A representative of Ernst & Young LLP is expected to be present at the annual meeting, with the opportunity to make a statement if the representative desires to do so, and is expected to be available to respond to appropriate questions.
 
Stockholder ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm is not required by our Bylaws or otherwise. However, the Board is submitting the selection of Ernst & Young LLP to the stockholders for ratification as a matter of good corporate practice. If the stockholders fail to ratify the selection, the Audit Committee will reconsider whether or not to retain that firm. Even if the selection is ratified, the Audit Committee in its discretion may direct the appointment of a different independent registered public accounting firm at any time during the year if it determines that such a change would be in the best interests of the company and its stockholders.
 
PRINCIPAL ACCOUNTING FEES AND SERVICES
 
The following table sets forth the aggregate fees billed to Halozyme for the fiscal years ended December 31, 2008 and December 31, 2007 by Ernst & Young LLP:

 	 	Fiscal 2008	 	 	Fiscal 2007	 	
 		
Audit Fees(1)	 	$	379,807	 	 	$	316,348	 	
Audit-Related Fees(2)	 	 	—	 	 	 	—	 	
Tax Fees(3)	 	$	70,000	 	 	 	—	 	
All Other Fees(4)	 	 	—	 	 	 	—	 	

 
			
(1)		Audit Fees consist of fees billed for professional services rendered for the audit of the company’s consolidated annual financial statements and review of the interim consolidated financial statements included in quarterly reports and services that are normally provided by our independent accountant in connection with statutory and regulatory filings or engagements. In addition to the Audit Fees for fiscal 2007 set forth above, we also made $15,000 of payments to our prior independent registered public accounting firm, Cacciamatta Accountancy Corporation (“Cacciamatta”) in connection with obtaining their consent contained in our Form 10-K filed on March 14, 2008. In addition to the Audit Fees for fiscal 2008 set forth above, we also made $26,500 of payments to Cacciamatta in connection with obtaining their consents contained in various filings made during 2008.	
 		
(2)		Audit-Related Fees consist of fees billed for assurance and related services that are reasonably related to the performance of the audit or review of our consolidated financial statements and are not reported under “Audit Fees.”	
 		
(3)		Tax Fees consist of fees billed for professional services rendered for tax compliance, tax advice and tax planning (domestic and international). These services include assistance regarding federal, state and international tax compliance, acquisitions and international tax planning.	
 		
(4)		All Other Fees consist of fees for products and services other than the services reported above.	
 
The Audit Committee’s policy is to pre-approve all audit and permissible non-audit services provided by our independent auditors. These services may include audit services, audit-related services, tax services and other services. Pre-approval is generally provided for up to one year and any pre-approval is detailed as to the particular service or category of services. The independent auditor and management are required to periodically report to the Audit Committee regarding the extent of services provided by the independent auditor in accordance with this pre-approval. The Chair of the Audit Committee is also authorized, pursuant to delegated authority, to pre-approve

7

 

additional services of up to $25,000 per engagement on a case-by-case basis, provided that such approvals are communicated to the full Audit Committee at its next meeting.
 
Vote Required and Board of Directors Recommendation
 
The affirmative vote of a majority of the votes cast at the meeting, at which a quorum is present, either in person or by proxy, shall ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2009. Abstentions and broker non-votes will each be counted as present for purposes of determining the presence of a quorum but will not have any effect on the outcome of the proposal.
 
The Board of Directors unanimously recommends a vote “FOR” the ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2009.

8

 
 
REPORT OF THE AUDIT COMMITTEE
 
The Audit Committee oversees Halozyme’s financial reporting process on behalf of the Board of Directors. The Audit Committee Charter describes in greater detail the responsibilities of the Audit Committee. Management has the primary responsibility for the financial statements and the reporting process, including internal control systems. Our independent auditor, Ernst & Young LLP, is responsible for expressing an opinion as to the conformity of our audited financial statements with generally accepted accounting principles.
 
The Audit Committee has reviewed and discussed the consolidated financial statements with management and Ernst & Young LLP. The Audit Committee has also discussed and reviewed with the auditors all matters required to be discussed by Statement on Auditing Standards No. 61, as amended (Communication with Audit Committees). The Audit Committee has met with Ernst & Young LLP, with and without management present, to discuss the overall scope of the Ernst & Young LLP audit, the results of its examinations, its evaluations of Halozyme’s internal controls and the overall quality of its financial reporting.
 
The Audit Committee has received from Ernst & Young LLP the written disclosures and the letter required by applicable requirements of the Public Company accounting Board regarding the independent accountant’s communications with the Audit Committee concerning independence, discussed with the auditors any relationships that may impact their objectivity and independence, and satisfied itself as to the auditors’ independence.
 
Based on the review and discussions referred to above, the Audit Committee recommended to the Board of Directors that Halozyme’s audited consolidated financial statements be included in Halozyme’s Annual Report on Form 10-K for the fiscal year ended December 31, 2008.
 
AUDIT COMMITTEE
 
Kathryn E. Falberg (Chair)
Kenneth J. Kelley
Steven T. Thornton

9

 
 
EXECUTIVE COMPENSATION
 
Compensation Discussion and Analysis
 
Goals of Compensation Program
 
The primary goals of our Compensation Committee with respect to the compensation of our executive officers are: (i) to attract and retain talented and dedicated executives; (ii) to tie annual cash incentives to the creation of stockholder value, as measured by the annual increase in our market capitalization; and (iii) to link long-term stock incentives to the achievement of specified company and individual performance criteria that we believe will lead to stockholder value creation. To achieve these goals, the Compensation Committee establishes compensation plans that tie a substantial portion of executives’ overall compensation to the achievement of key operational, clinical and financial goals. The Compensation Committee also reviews the performance of each individual executive officer against previously established individual performance criteria. Based upon data acquired through multiple sources, the Compensation Committee believes that the base salaries for our executive officers are comparable with executives in other companies of similar size and stage of development operating in our industry. When reviewing executive compensation policies, the Compensation Committee reviews executive compensation data generated by an independent third party, Radford Biotechnology Industry Survey, as well as compensation data obtained from other sources. The Compensation Committee seeks to establish an equity compensation structure that yields initial equity grants in the 75th percentile and annual refresher grants in the 50th percentile of similar companies.
 
Elements of Compensation
 
We have a relatively simple compensation structure that is comprised of: (i) base salary; (ii) annual cash and equity incentive awards; and (iii) stock options.
 
Base Salary
 
Base salaries for our executive officers are established based on the scope of their responsibilities, taking into account competitive market compensation paid by other companies for similar positions. Generally, we target salaries for our executive officers near the median of the range of salaries for executives in similar positions with similar responsibilities and experience at comparable companies. Base salaries are reviewed annually, and adjusted from time to time to realign salaries with market levels after taking into account individual responsibilities, performance and experience as well as the company’s financial position. Annual salaries for 2008 are reflected below in the table entitled “2008 Summary Compensation Table.” Annual salaries for 2009 were established by the Compensation Committee in February of 2009, and the annual base salaries for certain executive officers named in the 2008 Summary Compensation Table were set at the following levels:

Name	 	2009 Annual Base Salary	 	
 		
Jonathan E. Lim	 	$	395,000	 	
Gregory I. Frost	 	$	375,000	 	
Robert L. Little	 	$	334,000	 	
William J. Fallon	 	$	287,000	 	
David A. Ramsay	 	$	270,000	 	

2008 Senior Executive Incentive Structure (Cash Component)
 
The 2008 Senior Executive Incentive Structure, which we established to govern the cash and equity-based bonus awards to senior executive officers for 2008, based the size of the cash award pool upon the appreciation of Halozyme common stock (and the corresponding increase to Halozyme’s market capitalization) in 2008. The aggregate amount of the cash bonus pool was to be an escalating percentage of the overall increase to Halozyme’s market capitalization, as described below.
 
If our stock had appreciated during 2008, the aggregate cash pool would have equaled a percentage of Halozyme’s overall increase in market capitalization (as adjusted to remove the impact of any shares issued during 2008). The applicable percentage represented one-one hundredth of the year-over-year increase to the adjusted

10

 

market capitalization with a maximum applicable percentage of 2% (based on increases to market capitalization of 200% or greater). As the overall market capitalization increased, the percentage used to calculate the aggregate cash pool would also increase. For example, a 10% increase in adjusted 2008 market capitalization would have resulted in a cash award pool of approximately $50,000 and a 40% increase in adjusted 2008 market capitalization would have resulted in a cash award pool of roughly $850,000. Greater amounts of stock appreciation would have resulted in significantly larger cash award pools. For purposes of reference, cash awards to senior executive officers under the 2007 incentive program were not conditioned on an increase in market capitalization (cash awards were based on the accomplishment of various corporate and personal performance criteria) and the aggregate cash amount awarded to senior executive officers under the 2007 incentive program was approximately $440,000.
 
Once the size of the cash pool was established, our Chief Executive Officer would then make a recommendation to the Compensation Committee on the allocation of the pool among the senior executive officers eligible to participate in the pool, with the allocation being based on the individual’s achievement during 2008 of previously established personal goals. Our Board of Directors authorized the Compensation Committee to make the ultimate determination on the amount of senior executive cash awards, and the Compensation Committee had the flexibility of approving an aggregate cash award pool that was higher or lower than the aggregate amount determined pursuant to the calculation described in the paragraph above.
 
Our market capitalization did not increase in 2008, therefore no aggregate cash pool was established under the 2008 Senior Executive Incentive Structure and no cash awards were approved by the Compensation Committee.
 
2008 Senior Executive Incentive Structure (Equity Component)
 
Maximum equity awards were also established for each senior executive officer (amounts for selected members of senior management are set forth below in the table entitled “2008 Grants of Plan-Based Awards”) and the actual amounts awarded to each senior executive officer were based upon the accomplishment of individual performance criteria during 2008, with the equity award for the Chief Executive Officer being based upon the accomplishment of corporate performance criteria during 2008. The performance criteria applicable to the senior executive officers vary from position to position, but these criteria typically contain operational, strategic and developmental elements. The company performance criteria for 2008 which were used in determining the equity award for the Chief Executive Officer contained operational, clinical and financial elements that resulted from a collaborative process between the Chief Executive Officer and members of senior management. Specific criteria included: (i) business and development goals relating to our existing corporate partners; (ii) clinical and strategic goals relating to products and product candidates; (iii) production goals relating to the supply of product for clinical and commercial programs; (iv) business and development goals applicable to new transactions; and (v) annual revenue, cash burn and end of year cash balance targets. The Compensation Committee determined that roughly 80% of the company goals were met in 2008. To be eligible for an equity award, a member of senior management had to meet at least 75% of that person’s performance criteria.
 
Stock Options
 
Our 2008 Stock Plan authorizes us to grant options to purchase shares of common stock to our employees, directors and consultants, and our Compensation Committee is the administrator of this stock plan. Stock option grants are made in connection with the commencement of employment and may also be made following a significant change in job responsibilities or to meet other special retention or performance objectives. The Compensation Committee reviews and approves initial stock option awards for executive officers based upon a review of competitive compensation data. In appropriate circumstances, the Compensation Committee considers the recommendations of our Chief Executive Officer when determining the amount of an initial option grant or the amount of an annual incentive option grant for executive officers. While we awarded stock options to our executive officers pursuant to our 2008 Senior Executive Incentive Structure, those awards were not made until the first quarter of 2009. Stock options granted by us have an exercise price equal to the fair market value of our common stock on the day of grant, typically vest 25% per annum based upon continued employment over a four-year period, and generally expire ten years after the date of grant. Incentive stock options also include certain other terms necessary to assure compliance with the Internal Revenue Code of 1986, as amended.

11

 

2009 Senior Executive Incentive Plan (Cash Component)
 
The 2009 Senior Executive Incentive Plan establishes a cash award pool based upon the appreciation of Halozyme common stock (and the corresponding increase to Halozyme’s market capitalization) in 2009. If our common stock does not appreciate during 2009, there will be no cash award pool for senior executive officers under the 2009 Senior Executive Incentive Plan. If our market capitalization does appreciate during 2009 (based upon the trading average for the last 10 trading days of 2008 compared to the last 10 trading days of 2009), the size of the cash pool will equal a percentage of the overall increase in market capitalization (as adjusted to remove the impact of any shares issued during the course of 2009). The applicable percentage will not be a flat percentage, but will instead represent one one-hundredth of the year-over-year percentage increase to the adjusted market capitalization with a maximum applicable percentage of 2% (based on increases to market capitalization of 200% or greater). In addition, if the aggregate increase to market capitalization is less than roughly 30 percent, the cash award pool dictated by the previously described formula will be reduced by 50%. For example, in the event of a 10% increase in adjusted market capitalization the formula described above results in a cash award pool of approximately $43,000, but due to the 50% reduction feature the actual pool available for senior executive cash awards will be reduced to approximately $21,500. Increases in market capitalization greater than roughly 30% will not be subject to the reduction feature (for example, a 50% increase in adjusted market capitalization will result in a cash award pool of roughly $1,076,000). Greater amounts of market capitalization appreciation will result in significantly larger cash award pools. Once the size of the cash pool is established, Halozyme’s Chief Executive Officer will make a recommendation to the Compensation Committee on the allocation of the pool among the senior executive officers eligible to participate in the pool and the Compensation Committee will have the flexibility of approving an aggregate amount of cash awards that is higher or lower than the aggregate amount determined pursuant to the calculation described above.
 
2009 Senior Executive Incentive Plan (Equity Component)
 
The Compensation Committee has established maximum equity awards for each senior executive officer and the actual amounts to be awarded to each senior executive officer will be based upon the accomplishment of individual performance criteria during 2009, with the equity award for the Chief Executive Officer being based upon the accomplishment of corporate performance criteria during 2009. The performance criteria applicable to the senior executive officers vary from position to position, but these criteria typically contain operational, strategic and developmental elements. The company performance criteria for 2009 which will be used in determining the equity award for the Chief Executive Officer reflect operational, clinical and financial elements that result from a collaborative process between the Chief Executive Officer, members of senior management and the Board of Directors. Specific criteria include: (i) business and development goals relating to our existing corporate partners; (ii) clinical and strategic goals relating to products and product candidates; (iii) production goals relating to the supply of product for clinical and commercial programs; (iv) business and development goals applicable to new transactions; and (v) annual revenue, cash burn and end of year cash balance targets. The Compensation Committee determined that roughly 80% of the company goals were met in both 2007 and 2008 and we anticipate the goals for 2009 will be similar in difficulty to the goals established in prior years. To be eligible for an equity award, a member of senior management must meet at least 75% of that person’s performance criteria.
 
10b5-1 Trading Plans
 
In March of 2007 our Board of Directors adopted a policy that provides for the use of pre-arranged trading plans by persons subject to the company’s insider trading policy. All such pre-arranged trading plans must (i) comply with certain specified guidelines, including volume limitations, (ii) be approved by a committee consisting of independent directors and the company’s Chief Financial Officer and (iii) comply with Rule 10b5-1 established by the Securities and Exchange Commission. We believe that pre-arranged trading provides insiders with an opportunity to diversify their holdings in a measured process that also complies with the insider trading rules promulgated by the Securities and Exchange Commission. Certain of our officers and directors may establish pre-arranged trading plans in the future.

12

 

Potential Components of Compensation
 
In addition to granting incentive and nonstatutory stock options, our 2008 Stock Plan provides for the granting of restricted stock, restricted stock units, stock appreciation rights, performance units and shares and other stock-based awards. The Compensation Committee may utilize some or all of these types of awards for executive officers if it believes that such awards are necessary to further the goals of the compensation program.
 
Compensation Committee Report
 
We, the Compensation Committee of the Board of Directors of Halozyme Therapeutics, Inc., have reviewed and discussed the Compensation Discussion and Analysis contained in this Proxy Statement with management. Based on such review and discussion, we have recommended to the Board of Directors that the Compensation Discussion and Analysis be included in this Proxy Statement and in Halozyme’s Annual Report on Form 10-K for the fiscal year ended December 31, 2008.
 
THE COMPENSATION COMMITTEE
 
Steven T. Thornton (Chair)
Kenneth J. Kelley
Randal J. Kirk

13

 
Compensation Committee Interlocks and Insider Participation
 
None of the members of the Compensation Committee are or have been an officer or employee of Halozyme Therapeutics, Inc. During fiscal 2008, no member of the Compensation Committee had any relationship with Halozyme Therapeutics, Inc. requiring disclosure under Item 404 of Regulation S-K. During fiscal 2008, none of Halozyme’s executive officers served on the compensation committee (or its equivalent) or board of directors of another entity any of whose executive officers served on Halozyme’s Compensation Committee or Board of Directors.
 
Summary Compensation Table
 
The following table sets forth information concerning the compensation earned during the fiscal years ended December 31, 2008, 2007 and 2006 by our Chief Executive Officer, Chief Financial Officer, and our four other most highly compensated executive officers during the fiscal year ended December 31, 2008.
 
2008 SUMMARY COMPENSATION TABLE

 	 	 	 	 	 	 	 	 	 	 	 	 	 	Non-Equity	 	 	 	 	 	 	 	
 	 	 	 	 	 	 	 	 	 	 	 	 	 	Incentive Plan	 	 	All Other	 	 	 	 	
 	 	 	 	 	Salary	 	 	Bonus	 	 	Option	 	 	Compensation	 	 	Compensation	 	 	Total	 	
Name and Principal Position	 	Year	 	 	($)	 	 	($)(1)	 	 	Awards ($)(2)	 	 	($)(1)	 	 	($)	 	 	($)	 	
 		
Jonathan E. Lim	 	 	2008	 	 	 	375,000	 	 	 	—	 	 	 	253,054	 	 	 	—	 	 	 	468	 	 	 	628,522	 	
President and Chief	 	 	2007	 	 	 	356,250	 	 	 	—	 	 	 	263,873	 	 	 	50,000	 	 	 	407	 	 	 	670,530	 	
Executive Officer	 	 	2006	 	 	 	300,000	 	 	 	—	 	 	 	74,352	 	 	 	53,550	 	 	 	246	 	 	 	428,148	 	
Gregory I. Frost	 	 	2008	 	 	 	323,000	 	 	 	—	 	 	 	144,163	 	 	 	—	 	 	 	393	 	 	 	467,556	 	
Vice President and	 	 	2007	 	 	 	261,467	 	 	 	—	 	 	 	62,683	 	 	 	67,600	 	 	 	290	 	 	 	392,040	 	
Chief Scientific Officer	 	 	2006	 	 	 	210,000	 	 	 	—	 	 	 	93,855	 	 	 	31,500	 	 	 	188	 	 	 	335,543	 	
David A. Ramsay	 	 	2008	 	 	 	260,000	 	 	 	—	 	 	 	110,533	 	 	 	—	 	 	 	302	 	 	 	370,835	 	
Vice President and	 	 	2007	 	 	 	231,317	 	 	 	—	 	 	 	70,350	 	 	 	54,600	 	 	 	247	 	 	 	356,514	 	
Chief Financial Officer	 	 	2006	 	 	 	180,000	 	 	 	—	 	 	 	60,942	 	 	 	25,650	 	 	 	162	 	 	 	266,754	 	
William J. Fallon(3)	 	 	2008	 	 	 	270,000	 	 	 	—	 	 	 	83,991	 	 	 	—	 	 	 	317	 	 	 	354,308	 	
Vice President —	 	 	2007	 	 	 	255,000	 	 	 	20,000	(4)	 	 	62,704	 	 	 	66,900	 	 	 	136,442	(5)	 	 	541,046	 	
Manufacturing and Operations	 	 	2006	 	 	 	39,721	 	 	 	 	 	 	 	8,933	 	 	 	—	 	 	 	14,358	(6)	 	 	63,012	 	
Robert L. Little(7)	 	 	2008	 	 	 	322,000	 	 	 	—	 	 	 	106,873	 	 	 	—	 	 	 	392	 	 	 	429,265	 	
Vice President and Chief	 	 	2007	 	 	 	307,400	 	 	 	—	 	 	 	84,157	 	 	 	76,100	 	 	 	351	 	 	 	468,008	 	
Commercial Officer	 	 	2006	 	 	 	144,141	 	 	 	—	 	 	 	29,608	 	 	 	21,750	 	 	 	120	 	 	 	195,619	 	
Richard C. Yocum(8)	 	 	2008	 	 	 	300,000	 	 	 	—	 	 	 	105,899	 	 	 	—	 	 	 	360	 	 	 	406,259	 	
Vice President — Clinical	 	 	2007	 	 	 	268,500	 	 	 	—	 	 	 	81,030	 	 	 	70,900	 	 	 	306	 	 	 	420,736	 	
Development and Medical Affairs	 	 	2006	 	 	 	240,000	 	 	 	—	 	 	 	56,968	 	 	 	36,000	 	 	 	232	 	 	 	333,200	 	

 
			
(1)		Performance-based bonuses are generally paid pursuant to our annual incentive plans and reported as Non-Equity Incentive Plan Compensation. Except as otherwise noted, amounts reported as Bonus represent discretionary bonuses in addition to the amount (if any) earned under an annual incentive plan.	
 		
(2)		Valuation based on the dollar amount recognized for financial statement reporting purposes pursuant to revised Statement of Financial Accounting Standards No. 123 (“FAS 123R”). The assumptions used with respect to the valuation of option grants are set forth in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2008 filed with the SEC on March 13, 2009.	
 		
(3)		Mr. Fallon joined Halozyme in November of 2006 as Vice President — Manufacturing and Operations.	
 		
(4)		Represents Mr. Fallon’s sign-on bonus.	
 		
(5)		Includes the reimbursement of $75,222 in relocation expenses as well as a $60,927 tax gross-up payment.	
 		
(6)		Includes the reimbursement of $7,919 in relocation expenses as well as a $6,414 tax gross-up payment.	
 		
(7)		Mr. Little joined Halozyme in July of 2006 as Vice President & Chief Commercial Officer.	
 		
(8)		Dr. Yocum’s employment with Halozyme terminated on January 6, 2009.	

14

 

Grants of Plan-Based Awards
 
The following table sets forth certain information with respect to plan-based awards granted during the fiscal year ended December 31, 2008 to our named executive officers:
 
2008 GRANTS OF PLAN-BASED AWARDS

 	 	 	 	 	Estimated Future Payouts	 	 	 	 	
 	 	 	 	 	Under Non-Equity Incentive	 	 	Estimated Future Payouts Under	 	
 	 	 	 	 	Plan Awards(1)	 	 	Equity Incentive Plan Awards(1)	 	
Name	 	Grant Date	 	 	Threshold ($)	 	 	Maximum ($)(2)	 	 	Threshold (#)	 	 	Maximum (#)(3)	 	
 		
Jonathan E. Lim	 	 	4/16/2008	 	 	 	n/a	 	 	 	n/a	 	 	 	112,500	 	 	 	150,000	(4)	
Gregory I. Frost	 	 	4/16/2008	 	 	 	n/a	 	 	 	n/a	 	 	 	30,000	 	 	 	40,000	(5)	
David A. Ramsay	 	 	4/16/2008	 	 	 	n/a	 	 	 	n/a	 	 	 	30,000	 	 	 	40,000	(6)	
William J. Fallon	 	 	4/16/2008	 	 	 	n/a	 	 	 	n/a	 	 	 	30,000	 	 	 	40,000	(7)	
Robert L. Little	 	 	4/16/2008	 	 	 	n/a	 	 	 	n/a	 	 	 	30,000	 	 	 	40,000	(8)	
Richard C. Yocum	 	 	4/16/2008	 	 	 	n/a	 	 	 	n/a	 	 	 	30,000	 	 	 	40,000	(9)	

 
			
(1)		Our Board of Directors approved a performance-based incentive plan on April 16, 2008 that provided for cash and equity awards based upon the accomplishment of specified company and individual performance criteria in 2008. For a description of the elements of the incentive plan, please see “Compensation Discussion and Analysis — 2008 Senior Executive Incentive Structure (Cash Component) ” and “Compensation Discussion and Analysis — 2008 Senior Executive Incentive Structure (Equity Component). ” The actual amount of cash paid to each named executive officer pursuant to the incentive plan established for 2008 is set forth in the Summary Compensation Table under the heading, “Non-Equity Incentive Plan Compensation.”	
 		
(2)		Because a cash pool was to be established under the 2008 incentive plan based on the appreciation of the company’s common stock throughout the year and because that cash pool was to be allocated at the discretion of our Chief Executive Officer, subject to the approval of our Board of Directors, it is impossible to determine threshold and maximum cash awards for our senior executive officers. On February 5, 2009 the Compensation Committee determined that no cash awards would be granted to the senior executive officers.	
 		
(3)		Maximum equity awards for each executive officer under the 2008 incentive plan were derived from data relating to the equity awards granted by comparable companies.	
 		
(4)		An option to purchase 120,000 shares of common stock was granted to this executive officer on February 5, 2009 pursuant to the performance-based incentive plan established for 2008. One-fourth of the shares subject to the grant will vest on the one year anniversary of the grant, and 1/48 of the shares will vest monthly thereafter. The exercise price of this option is $6.10 per share.	
 		
(5)		An option to purchase 80,000 shares of common stock was granted to this executive officer on February 5, 2009 pursuant to the performance-based incentive plan established for 2008. One-fourth of the shares subject to the grant will vest on the one year anniversary of the grant, and 1/48 of the shares will vest monthly thereafter. The exercise price of this option is $6.10 per share.	
 		
(6)		An option to purchase 30,000 shares of common stock was granted to this executive officer on February 5, 2009 pursuant to the performance-based incentive plan established for 2008. One-fourth of the shares subject to the grant will vest on the one year anniversary of the grant, and 1/48 of the shares will vest monthly thereafter. The exercise price of this option is $6.10 per share.	
 		
(7)		An option to purchase 40,000 shares of common stock was granted to this executive officer on February 5, 2009 pursuant to the performance-based incentive plan established for 2008. One-fourth of the shares subject to the grant will vest on the one year anniversary of the grant, and 1/48 of the shares will vest monthly thereafter. The exercise price of this option is $6.10 per share.	
 		
(8)		An option to purchase 20,000 shares of common stock was granted to this executive officer on February 5, 2009 pursuant to the performance-based incentive plan established for 2008. One-fourth of the shares subject to the grant will vest on the one year anniversary of the grant, and 1/48 of the shares will vest monthly thereafter. The exercise price of this option is $6.10 per share.	
 		
(9)		This executive officer was not granted an option because his employment had terminated prior to February 5, 2009.	

15

 

Outstanding Equity Awards at Fiscal Year-End
 
The following table sets forth certain information with respect to the value of all unexercised options previously awarded to our named executive officers as of December 31, 2008:
 
OUTSTANDING EQUITY AWARDS AT DECEMBER 31, 2008

 	 	Number of	 	 	Number of	 	 	 	 	 	 	 	
 	 	Securities	 	 	Securities	 	 	 	 	 	 	 	
 	 	Underlying	 	 	Underlying	 	 	 	 	 	 	 	
 	 	Unexercised	 	 	Unexercised	 	 	Option	 	 	Option	 	
 	 	Options(#)	 	 	Options (#) (1)	 	 	Exercise	 	 	Expiration	 	
Name	 	Exercisable	 	 	Unexercisable	 	 	Price ($)	 	 	Date	 	
 		
Jonathan E. Lim	 	 	1,076,029	 	 	 	—	 	 	 	0.39	 	 	 	11/11/13	 	
 	 	 	559,949	 	 	 	—	 	 	 	0.39	 	 	 	11/11/13	 	
 	 	 	241,665	 	 	 	8,335	(2)	 	 	2.05	 	 	 	10/13/14	 	
 	 	 	53,422	 	 	 	—	 	 	 	2.02	 	 	 	12/8/14	 	
 	 	 	24,202	 	 	 	15,401	(4)	 	 	7.51	 	 	 	2/5/17	 	
 	 	 	—	 	 	 	50,000	 	 	 	5.60	 	 	 	2/6/18	 	
Gregory I. Frost	 	 	55,000	 	 	 	5,000	(3)	 	 	2.05	 	 	 	10/13/14	 	
 	 	 	51,751	 	 	 	—	 	 	 	2.02	 	 	 	12/8/14	 	
 	 	 	9,612	 	 	 	6,117	(4)	 	 	7.51	 	 	 	2/5/17	 	
 	 	 	—	 	 	 	50,000	 	 	 	5.60	 	 	 	2/6/18	 	
David A. Ramsay	 	 	354,950	 	 	 	—	 	 	 	0.39	 	 	 	11/11/13	 	
 	 	 	45,833	 	 	 	4,167	(3)	 	 	2.05	 	 	 	10/13/14	 	
 	 	 	46,745	 	 	 	—	 	 	 	2.02	 	 	 	12/8/14	 	
 	 	 	7,910	 	 	 	5,033	(4)	 	 	7.51	 	 	 	2/5/17	 	
 	 	 	—	 	 	 	28,800	 	 	 	5.60	 	 	 	2/6/18	 	
William J. Fallon	 	 	83,333	 	 	 	76,667	 	 	 	2.67	 	 	 	11/9/16	 	
 	 	 	—	 	 	 	28,800	 	 	 	5.60	 	 	 	2/6/18	 	
Robert L. Little	 	 	120,833	 	 	 	79,167	 	 	 	2.33	 	 	 	7/27/16	 	
 	 	 	6,637	 	 	 	4,224	(4)	 	 	7.51	 	 	 	2/5/17	 	
 	 	 	—	 	 	 	28,800	 	 	 	5.60	 	 	 	2/6/18	 	
Richard C. Yocum	 	 	87,500	 	 	 	16,667	 	 	 	1.87	 	 	 	5/12/15	 	
 	 	 	10,985	 	 	 	6,991	(4)	 	 	7.51	 	 	 	2/5/17	 	
 	 	 	—	 	 	 	28,800	 	 	 	5.60	 	 	 	2/6/18	 	

 
			
(1)		Except as otherwise noted, each option vests at the rate of 1/4 of the underlying shares on the first anniversary of the date of grant and 1/48 of the shares each month thereafter.	
 		
(2)		The option vests at the rate of 1/20 of the underlying shares on February 1, 2007, and 1/20 of the underlying shares each month thereafter until January 1, 2008, and then 1/30 of the underlying shares each month thereafter.	
 		
(3)		The option vests at the rate of 1/12 of the underlying shares on February 1, 2008, and 1/12 of the underlying shares each month thereafter.	
 		
(4)		The option vests at the rate of 1/3 of the underlying shares on February 5, 2008, and 1/36 of the underlying shares each month thereafter.	

16

 

Option Exercises and Stock Vested During Last Fiscal Year
 
No named executive officer has a restricted stock grant, restricted stock unit or other similar instrument. The following table sets forth certain information with respect to the exercise of stock options by our named executive officers during the fiscal year ended December 31, 2008:
 
OPTION EXERCISES AND STOCK VESTED

 	 	Option Awards	 	
 	 	Number of Shares	 	 	Value Realized on	 	
 	 	Acquired on Exercise	 	 	Exercise	 	
Name	 	(#)	 	 	($)	 	
 		
Jonathan E. Lim	 	 	230,000	 	 	 	1,304,100	 	
Gregory I. Frost	 	 	639,902	 	 	 	3,602,648	 	
David A. Ramsay	 	 	—	 	 	 	—	 	
William J. Fallon	 	 	—	 	 	 	—	 	
Robert L. Little	 	 	—	 	 	 	—	 	
Richard C. Yocum	 	 	—	 	 	 	—	 	

Potential Payments Upon Termination or Change in Control
 
Severance Policy
 
On February 6, 2008 the Board of Directors approved the adoption of a company-wide severance policy. Under the severance policy, the particular amount of cash severance for an employee terminated by the company without cause will generally be dictated by the employee’s position in the organization as well as the seniority of that employee. The severance policy is applicable to members of senior management in the following respects: (i) the cash severance for the Chief Executive Officer will be equal to the CEO’s then-current annual base salary; (ii) the cash severance for other officers will be equal to one half of the then-current annual base salary for such officers; and (iii) the cash severance for non-officer Vice Presidents will initially be equal to ten weeks worth of the then-current annual base salary for such employee, provided that the employee will get an additional two weeks of severance pay for each year of employment with the company (up to a maximum of 26 weeks). Cash payments under the severance policy will normally be made in a lump sum payment, subject to standard taxes and withholdings, and will be conditioned upon the receipt of a release of claims from the impacted employee. In addition to cash severance payments, the company will also pay certain health coverage costs during the term of the applicable severance period. Despite the establishment of the severance policy, however, the Board of Directors retains the right to amend, alter or terminate the severance policy at any time. Assuming: (i) each of the named executive officers was terminated without cause on December 31, 2008; and (ii) each named executive officer executed a release of claims in a form satisfactory to the company, the named executive officers would have received the following amounts pursuant to the severance policy:

 	 	Lump Sum	 	 	Duration of Health	 	
Name	 	Severance Payment	 	 	Coverage Continuation(1)	 	
 		
Jonathan E. Lim	 	$	375,000	 	 	 	One year	 	
Gregory I. Frost	 	$	161,500	 	 	 	Six months	 	
David A. Ramsay	 	$	130,000	 	 	 	Six months	 	
William J. Fallon	 	$	135,000	 	 	 	Six months	 	
Robert L. Little	 	$	161,000	 	 	 	Six months	 	
Richard C. Yocum	 	$	150,000	 	 	 	Six months	 	

 
			
(1)		The per month cost for continued health care coverage will vary for each employee based upon the individual coverage circumstances for each such employee.	

17

 

Change in Control
 
Options granted to employees and officers of Halozyme under our 2001 Stock Plan and 2004 Stock Plan, and to certain officers under our 2008 Stock Plan, provide for full acceleration of the unvested portion of an option if the employee or officer is terminated without cause or resigns for certain specified reasons following certain change in control events. In addition, in April 2008 our Board of Directors adopted a Change in Control Policy applicable to senior executive officers. This policy provides for cash payments, continued healthcare coverage and accelerated vesting of subsequently granted equity awards for any senior executive officer who is terminated for a reason other than cause within twelve months of a change in control transaction. The cash payments, to be made in a lump sum payment, will equal a multiple of the senior executive’s then-current base salary (twice the salary of the Company’s Chief Executive Officer and one and a half times the salary of all other senior executives). The Company will also pay for continued healthcare coverage post-termination for a period of eighteen months for the Chief Executive Officer and twelve months for all other senior executives. The Change of Control Policy also provides that the gross amount payable to a senior executive officer under the policy may be reduced in the event that such reduction will result in a greater net payment (after taking into account the effect of tax laws applicable to such change in control payments) to the senior executive officer. We have entered into agreements with each senior executive officer that document the specific terms of the Change in Control Policy applicable to such officer.
 
Assuming a change in control took place on December 31, 2008 and each of the named executive officers was terminated without cause immediately following the change in control, the foregoing individuals would have received the following amounts as a result of such terminations.

 	 	Potential Payments	 	 	 	 	 	 	 	
 	 	Upon Change in	 	 	Potential Payments Upon	 	 	Total Payments Upon	 	
Name	 	Control(1)	 	 	Change in Control(2)	 	 	Change in Control	 	
 		
Jonathan E. Lim	 	$	29,589	 	 	$	750,000	 	 	$	779,589	 	
Gregory I. Frost	 	$	31,822	 	 	$	484,500	 	 	$	516,322	 	
David A. Ramsay	 	$	29,586	 	 	$	390,000	 	 	$	419,586	 	
William J. Fallon	 	$	—	 	 	$	405,000	 	 	$	405,000	 	
Robert L. Little	 	$	—	 	 	$	483,000	 	 	$	483,000	 	
Richard C. Yocum	 	$	62,168	 	 	$	450,000	 	 	$	512,168	 	

 
			
(1)		Amounts shown in this column reflect the value of unvested options that would have accelerated if the named executive officer was terminated on December 31, 2008 in connection with a change in control based upon the difference between the closing price ($5.60) of our common stock on that date and the exercise price of the respective options. There can be no assurance that the options will ever be exercised (in which case no value will actually be realized by the executive) or that the value on exercise will be equal to the value shown in this column.	
 		
(2)		Amounts shown in this column reflect the value of cash payments to be made to the senior executive officer in connection with the change in control agreement currently in place with such officer. These change in control agreements also provide for the continued payment of healthcare coverage post-termination, but the exact amount of such payments will vary for each employee based upon the individual coverage circumstances for each such employee, and an estimate of such payment amounts is not included in this column.	

18

 
 
Compensation of Directors
 
The following table sets forth information concerning the compensation earned during the fiscal year ended December 31, 2008 by each individual who served as a director at any time during the fiscal year:
 
2008 DIRECTOR COMPENSATION

 	 	Fees Earned or	 	 	 	 	 	 	 	 	 	 	
 	 	Paid in Cash	 	 	Stock Awards	 	 	Option Awards	 	 	 	 	
Name	 	($)	 	 	($)(1)	 	 	($)(1)(2)	 	 	Total ($)	 	
 		
Kenneth J. Kelley	 	 	85,000	 	 	 	104,999	 	 	 	42,663	 	 	 	232,662	 	
Robert L. Engler	 	 	40,000	 	 	 	104,999	 	 	 	42,663	 	 	 	187,662	 	
Kathryn E. Falberg(3)	 	 	83,750	 	 	 	104,999	 	 	 	42,663	 	 	 	231,412	 	
Randal J. Kirk(4)	 	 	42,500	 	 	 	104,999	 	 	 	42,663	 	 	 	190,162	 	
Connie L. Matsui(5)	 	 	40,000	 	 	 	104,999	 	 	 	42,663	 	 	 	187,662	 	
John S. Patton	 	 	30,000	 	 	 	104,999	 	 	 	42,663	 	 	 	177,662	 	
Steven T. Thornton(6)	 	 	58,750	 	 	 	104,999	 	 	 	42,663	 	 	 	206,412	 	

 
			
(1)		Valuation based on the dollar amount recognized for financial statement reporting purposes pursuant to FAS 123R. The assumptions used with respect to the valuation of option grants are set forth in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2008 filed with the SEC on March 13, 2009.	
 		
(2)		Under the 2005 Outside Directors’ Plan (the “2005 Plan”), non-employee directors received annual stock option grants of 10,000 shares. Stock options granted in May of 2008 to the non-employee directors represented the last option grants that could be made under the 2005 Plan. Going forward, the terms of the 2008 Outside Directors’ Plan will apply to equity awards for non-employee directors.	
 		
(3)		Ms. Falberg’s cash fees include a pro rata payment for a partial year’s service on the Nominating and Governance Committee.	
 		
(4)		Mr. Kirk’s cash fees include a pro rata payment for a partial year’s service on the Compensation Committee.	
 		
(5)		Ms. Matsui’s cash fees include a pro rata payment for a partial year’s service on the Audit Committee, Compensation Committee and Nominating and Governance Committee.	
 		
(6)		Mr. Thornton’s cash fees include a pro rata payment for a partial year’s service on the Audit Committee.	
 
Under the 2008 Outside Directors’ Plan, an outside director receives an initial restricted stock grant of 20,000 shares of common stock upon joining the Board. This initial restricted stock grant will vest upon the later of: (a) the first day that the outside director may trade our stock in compliance with our Insider Trading Policy that occurs after the six month anniversary of the date of grant or (b) the first day that the outside director may trade our stock in compliance with our Insider Trading Policy that occurs after the date of the first annual meeting following the initial restricted stock grant. Outside directors also automatically receive annual restricted stock grants of 20,000 shares of common stock immediately following future annual meetings of stockholders. This annual restricted stock grant will vest on the first day that the outside director may trade our stock in compliance with our Insider Trading Policy that occurs after the date immediately preceding the annual meeting following the date of grant.
 
Outside directors receive an annual retainer of $30,000 for service on the Board as well as an annual retainer for service on any committee of the Board. Outside directors serving on the Board’s Audit Committee will receive an annual retainer of $15,000, provided that the Chair of that committee will receive an annual retainer of $30,000. Outside directors serving on the Board’s Compensation Committee will receive an annual retainer of $10,000, provided that the Chair of that committee will receive an annual retainer of $20,000. Outside directors serving on the Board’s Nominating and Governance Committee will receive an annual retainer of $5,000, provided that the Chair of that committee will receive an annual retainer of $10,000. Lastly, an outside director serving as the Chair of the Board of Directors will receive an annual retainer of $30,000.
 
Halozyme directors who are also employees of Halozyme do not receive any compensation for their services as members of the Board of Directors.

19

 

EQUITY COMPENSATION PLAN INFORMATION
 
The following table sets forth information regarding outstanding options and shares reserved for future issuance under our current equity compensation plans as of December 31, 2008:

 	 	 	 	 	 	 	 	Number of Shares	 	
 	 	 	 	 	 	 	 	Remaining Available	 	
 	 	 	 	 	 	 	 	for Future Issuance	 	
 	 	Number of Shares to	 	 	 	 	 	under Equity	 	
 	 	Be Issued upon	 	 	Weighted-Average	 	 	Compensation Plans	 	
 	 	Exercise of	 	 	Exercise Price of	 	 	(Excluding Shares	 	
 	 	Outstanding Options,	 	 	Outstanding Options,	 	 	Reflected in	 	
 	 	Warrants and Rights	 	 	Warrants and Rights	 	 	Column(a))	 	
Plan Category	 	(a)	 	 	(b)	 	 	(c)	 	
 		
Equity compensation plans approved by stockholders(1)	 	 	7,129,785	 	 	$	3.05	 	 	 	5,413,554	 	
Equity compensation plans not approved by stockholders(2)	 	 	125,000	 	 	$	1.25	 	 	 	—	 	
 	 	 	 	 	 	 	 	 	 	 	 	 	
Total	 	 	7,254,785	 	 	$	3.02	 	 	 	5,413,554	 	

 

			
(1)		Represents stock options under the 2008 Stock Plan, 2008 Outside Directors’ Stock Plan, 2006 Stock Plan, 2005 Outside Directors’ Stock Plan, 2004 Stock Plan and the 2001 Stock Plan. Options under the 2001 Stock Plan were assumed by Halozyme as part of the March 2004 merger between DeliaTroph Pharmaceuticals, Inc. and Global Yacht Services, Inc. The 2001 Stock Plan was approved by the shareholders of DeliaTroph prior to the merger and the former shareholders of DeliaTroph held approximately 90% of the voting stock of Halozyme immediately following the merger. No additional options will be granted under the 2001 Stock Plan.	
 		
(2)		Represents the grant by Halozyme to a non-executive employee of an option to purchase 125,000 shares of common stock at an exercise price of $1.25 per share through a nonstatutory stock option that is not under any of Halozyme’s existing stock plans. This option has a ten year term and vests at the rate of 1/4 of the shares on the first anniversary of the employee’s date of hire and 1/48 of the shares monthly thereafter. This option is fully vested.	
 
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
 
Pursuant to our Code of Conduct and Ethics, our executive officers, directors, and principal stockholders, including their immediate family members and affiliates, are prohibited from entering into transactions which create, or would appear to create, a conflict of interest with us. Our Audit Committee is responsible for reviewing and approving related party transactions. Our Audit Committee shall approve only those agreements that, in light of known circumstances, are in, or are not inconsistent with, our best interests, as our Audit Committee determines in the good faith exercise of its discretion.

20

 
 
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
 
The following table sets forth, as of March 1, 2009, certain information with respect to the beneficial ownership of our common stock by (i) each stockholder known by Halozyme to be the beneficial owner of more than 5% of our common stock, (ii) each director and director-nominee of Halozyme, (iii) each executive officer named in the Summary Compensation Table above, and (iv) all directors and executive officers of Halozyme as a group:

 	 	Number of Shares	 	 	 	 	
 	 	Beneficially	 	 	 	 	
Beneficial Owner(1)	 	Owned(2)	 	 	Percent(3)	 	
 		
Randal J. Kirk(4) )
The Governor Tyler, 1881 Grove Avenue Radford, Virginia 24141	 	 	15,317,869	 	 	 	18.5	 	
QVT Financial LP(5)
1177 Avenue of the Americas, 9th Floor New York, New York 10036	 	 	6,793,266	 	 	 	8.1	 	
Gregory I. Frost(6)	 	 	3,668,558	 	 	 	4.4	 	
Jonathan E. Lim(7)	 	 	2,660,502	 	 	 	3.1	 	
David A. Ramsay(8)	 	 	880,853	 	 	 	1.1	 	
Richard C. Yocum(9)	 	 	123,441	 	 	 	*	 	
Robert L. Little(10)	 	 	165,542	 	 	 	*	 	
William J. Fallon(11)	 	 	103,866	 	 	 	*	 	
John S. Patton(12)	 	 	225,000	 	 	 	*	 	
Kenneth J. Kelley(13)	 	 	40,000	 	 	 	*	 	
Robert L. Engler(14)	 	 	310,000	 	 	 	*	 	
Steven T. Thornton(15)	 	 	40,000	 	 	 	*	 	
Connie L. Matsui(16)	 	 	65,000	 	 	 	*	 	
Kathryn E. Falberg(17)	 	 	40,000	 	 	 	*	 	
Directors and executive officers as a group (12 persons)(18)	 	 	23,517,190	 	 	 	27.3	 	

 
			
* 		Less than 1%.	
 		
(1)		Except as otherwise indicated, the persons named in this table have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them, subject to community property laws where applicable and to the information contained in the footnotes to this table. Unless otherwise noted, the address for each beneficial owner is: c/o Halozyme Therapeutics, Inc., 11388 Sorrento Valley Rd., San Diego, CA 92121.	
 		
(2)		Under the rules of the Securities and Exchange Commission, a person is deemed to be the beneficial owner of shares that can be acquired by such person within 60 days upon the exercise of options or warrants.	
 		
(3)		Calculated on the basis of 82,946,449 shares of common stock outstanding as of March 1, 2009, provided that any additional shares of common stock that a stockholder has the right to acquire within 60 days after March 1, 2009, are deemed to be outstanding for the purpose of calculating that stockholder’s percentage beneficial ownership.	
 		
(4)		Based on the Form 4 filed by Randal J. Kirk with the SEC on July 14, 2008. Includes shares held by the following entities over which Mr. Kirk (or an entity over which he exercises exclusive control) exercises exclusive control: 522,460 shares held by RJK, L.L.C.; 1,436,186 shares held by Kirkfield, L.L.C.; 135,000 shares held by Third Security Staff 2001, LLC; 3,000,000 shares held by Radford Investments Limited Partnership; 2,189,050 shares held by Randal J. Kirk (2000) Limited Partnership; 1,326,320 shares held by New River Management IV, L.P., and 6,328,853 shares held by New River Management V, L.P. Also includes 10,000 shares subject to options that may be exercised within 60 days after March 1, 2009.	
 		
(5)		QVT Financial LP (“QVT Financial”) is the investment manager for QVT Fund LP (the “Fund”), which beneficially owns 5,391,225 shares of Common Stock, and for Quintessence Fund L.P. (“Quintessence”),	

21

 

			
		which beneficially owns 442,041 shares of Common Stock. QVT Financial has the power to direct the vote and disposition of the Common Stock held by the Fund and Quintessence. Accordingly, QVT Financial may be deemed to be the beneficial owner of an aggregate amount of 5,833,266 shares of Common Stock, consisting of the shares owned by the Fund and Quintessence. Also includes 960,000 shares subject to warrants that may be exercised within 60 days after March 1, 2009.	
 		
		QVT Financial GP LLC, as General Partner of QVT Financial, may be deemed to beneficially own the same number of shares of Common Stock reported by QVT Financial. QVT Associates GP LLC, as General Partner of the Fund and Quintessence, may be deemed to beneficially own the aggregate number of shares of Common Stock owned by the Fund and Quintessence, and accordingly, QVT Associates GP LLC may be deemed to be the beneficial owner of an aggregate amount of 5,833,266 shares of Common Stock. Each of QVT Financial and QVT Financial GP LLC disclaim beneficial ownership of the shares of Common Stock owned by the Fund and Quintessence. QVT Associates GP LLC disclaims beneficial ownership of all shares of Common Stock owned by the Fund and Quintessence, except to the extent of its pecuniary interest therein.	
 		
(6)		Includes 137,692 shares subject to options that may be exercised within 60 days after March 1, 2009.	
 		
(7)		Includes 1,980,502 shares subject to options that may be exercised within 60 days after March 1, 2009.	
 		
(8)		Includes 469,443 shares subject to options that may be exercised within 60 days after March 1, 2009.	
 		
(9)		Dr. Yocum’s employment with Halozyme terminated on January 6, 2009, and the amount of shares reported is based upon information provided by Dr. Yocum.	
 		
(10)		Includes 152,542 shares subject to options that may be exercised within 60 days after March 1, 2009.	
 		
(11)		Includes 103,866 shares subject to options that may be exercised within 60 days after March 1, 2009.	
 		
(12)		Includes 195,000 shares subject to options that may be exercised within 60 days after March 1, 2009.	
 		
(13)		Includes 10,000 shares subject to options that may be exercised within 60 days after March 1, 2009.	
 		
(14)		Includes 245,000 shares subject to options that may be exercised within 60 days after March 1, 2009.	
 		
(15)		Includes 10,000 shares subject to options that may be exercised within 60 days after March 1, 2009.	
 		
(16)		Includes 20,000 shares subject to options that may be exercised within 60 days after March 1, 2009.	
 		
(17)		Includes 10,000 shares subject to options that may be exercised within 60 days after March 1, 2009.	
 		
(18)		Includes 3,344,045 shares subject to options that may be exercised within 60 days after March 1, 2009 beneficially owned by all executive officers and directors. Dr. Yocum’s stock holdings are not included in this calculation.	
 
COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT
 
Section 16(a) of the Securities Exchange Act of 1934 requires our executive officers and directors and persons who beneficially own more than 10% of our common stock to file initial reports of beneficial ownership and reports of changes in beneficial ownership with the SEC. Each such person is required by SEC regulations to furnish us with copies of all Section 16(a) forms filed by such person.
 
Based solely on our review of such forms furnished to us and written representations from certain reporting persons, we believe that all filing requirements applicable to our executive officers, directors and greater-than-10% stockholders were met.
 
STOCKHOLDER PROPOSALS TO BE PRESENTED AT NEXT ANNUAL MEETING
 
Stockholder proposals may be included in our proxy materials for an annual meeting so long as they are provided to us on a timely basis and satisfy the other conditions set forth in applicable SEC rules. For a stockholder proposal to be included in our proxy materials for the 2010 annual meeting, the proposal must be received at our principal executive offices, addressed to the Secretary, not later than December 2, 2009. Stockholder business that is not intended for inclusion in our proxy materials may be brought before the annual meeting so long as we receive notice of the proposal as specified by our Bylaws, addressed to the Secretary at our principal executive offices, not later than December 2, 2009.

22

 

TRANSACTION OF OTHER BUSINESS
 
At the date of this Proxy Statement, the Board of Directors knows of no other business that will be conducted at the 2009 annual meeting other than as described in this Proxy Statement. If any other matter or matters are properly brought before the meeting, or any adjournment or postponement of the meeting, it is the intention of the persons named in the accompanying form of proxy to vote the proxy on such matters in accordance with their best judgment.
 
David A. Ramsay
 
Chief Financial Officer and Secretary
 
April 2, 2009

23

 

HALOZYME THERAPEUTICS, INC. DETACH PROXY CARD HERE HALOZYME THERAPEUTICS, INC. TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: Whether or not you plan to attend the meeting in person, you are urged to sign and promptly mail this proxy in the return envelope so that your stock may be represented at the meeting. THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” ALL PROPOSALS: 1. To elect Randal J. Kirk and John S. Patton as Class II Directors, to hold offi ce until the 2. To ratify the selection of Ernst & Young LLP as the Company’s independent 2012 Annual Meeting of Stockholders. registered public accounting fi rm for the fi scal year ending December 31, 2009. FOR ALL WITHHOLD ALL EXCEPTIONS FOR AGAINST ABSTAIN (INSTRUCTION: To withhold authority to vote for any individual nominee, mark the “Exceptions” box above and write the name of the nominee(s) that you do not wish to vote for on the line(s) below the “Exceptions” box.) Please sign below, exactly as name or names appear on this proxy. If the stock is registered in the names of two or more persons (Joint Holders), each should sign. When signing as attorney, executor, administrator, trustee, custodian, guardian or corporate offi cer, give printed name and full title. If more than one trustee, all should sign. Date: Stockholder Signature Date: Joint Holder Signature (if applicable) Please Detach Here You Must Detach This Portion of the Proxy Card Before Returning it in the Enclosed Envelope	

 

DETACH PROXY CARD HERE HALOZYME THERAPEUTICS, INC. PROXY PROXY SOLICITED BY THE BOARD OF DIRECTORS FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 7, 2009 The undersigned hereby appoints Jonathan E. Lim and David A. Ramsay, and each of them, as attorneys and proxies of the undersigned, with full power of substitution, to vote all of the shares of stock of Halozyme Therapeutics, Inc. (the “Company”) which the undersigned may be entitled to vote at the Annual Meeting of Stockholders of the Company to be held at the Halozyme Conference Center, 11404 Sorrento Valley Road, San Diego, California 92121, on Thursday, May 7, 2009, at 8:00 a.m. local time and at any and all adjournments or postponements thereof, with all powers that the undersigned would possess if personally present, upon and in respect of the following matters and in accordance with the following instructions, with discretionary authority as to any and all other matters that may properly come before the meeting. The shares represented by this proxy card will be voted as directed or, if this card contains no specifi c voting instructions, these shares will be voted in accordance with the recommendations of the Board of Directors. YOUR VOTE IS IMPORTANT. You are urged to complete, sign, date and promptly return the accompanying proxy in the enclosed envelope, which is postage prepaid if mailed in the United States. (Continued and to be signed on reverse side.)